PreadyPort-BCRP | BBB Assay | 고마바이오텍

특징   

• BCRP (breast cancer resistance protein; ABCG2)는 대한 기질 특이성을 가진 high-capacity efflux transport로, 장벽 조직 및 배설 기관의 apical cell membrane에 존재합니다. 
• PreadyPort-BCRP는 BCRP를 발현하는 12일 분화된 MDCK II cell이 미리 seeding된 24well 혹은 96 transwell insert plate 입니다.
• PMDA, FDA, EMA에서는 BCRP, MDR1/P-gp를 reference efflux transporter로서 이용하도록 권고하고 있습니다. 

종류  

• KRECE-BCP01 PreadyPort-BCRP (24 Transwell) 
• KRECE-BCP02 PreadyPort-BCRP/CTRL 1:1 (24 Transwell)
• KRECE-BCP50 PreadyPort-BCRP (96 Transwell)
• KRECE-BCP51 PreadyPort-BCRP/CTRL 1:1 (96 Transwell)

사용 과정

데이터 

사용 논문 

• Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012.

• Mukkavilli, R., Jadhav, G., Vangala, S. (2017). Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Current Pharmaceutical Biotechnology, Vol. 18, No. 14, pp. 1151-1158(8). https://doi.org/10.2174/1389201019666180308091855.

• ICH M12 Drug Interaction Studies, 2022.

• FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

• EMA Guideline on Investigation of Drug Interactions, 2012.

• PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.